Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Loss-of-function mutations in parkin are the major cause of early-onset familial Parkinson's disease. To investigate the pathogenic mechanism by which loss of parkin function causes Parkinson's disease, we generated a mouse model bearing a germline disruption in parkin. Parkin-/- mice are viable and exhibit grossly normal brain morphology. Quantitative in vivo microdialysis revealed an increase in extracellular dopamine concentration in the striatum of parkin-/- mice. Intracellular recordings of medium-sized striatal spiny neurons showed that greater currents are required to induce synaptic responses, suggesting a reduction in synaptic excitability in the absence of parkin. Furthermore, parkin-/- mice exhibit deficits in behavioral paradigms sensitive to dysfunction of the nigrostriatal pathway. The number of dopaminergic neurons in the substantia nigra of parkin-/- mice, however, is normal up to the age of 24 months, in contrast to the substantial loss of nigral neurons characteristic of Parkinson's disease. Steady-state levels of CDCrel-1, synphilin-1, and alpha-synuclein, which were identified previously as substrates of the E3 ubiquitin ligase activity of parkin, are unaltered in parkin-/- brains. Together these findings provide the first evidence for a novel role of parkin in dopamine regulation and nigrostriatal function, and a non-essential role of parkin in the survival of nigral neurons in mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, parkin-deficient mice and mice expressing a dominant negative form of Nrdp1 are not reported to have significant neurodegenerative disease171819.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“The lack of reported neurodegeneration in parkin-deficient and Nrdp1 mutant mice171819 makes it unlikely that this interaction explains our finding of neurodegeneration in Clec16a mutant mice.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“Although PINK1 (McWilliams et al, 2018) and PRKN (Goldberg et al, 2003; Perez & Palmiter, 2005) deficiency do not elicit major defects under baseline conditions, defective striatal neural plasticity is observed in prkn− / − mice (Kitada et al, 2009).”
From Autophagy in major human diseases (2021) · cites this paper as Goldberg et al, 2003
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
The unbiased estimation of number and sizes of arbitrary particles using the disector
Sterio, D. C. (1984) · Journal of Microscopy · doi:10.1111/j.1365-2818.1984.tb02501.x · Cited by 2,519
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Dunham, N. W., & Miya, T. S. (1957) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030460322 · Cited by 1,716
Association between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene
Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Denèfle, P., Wood, N. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422103 · Cited by 1,433
Schallert, T., Fleming, S. M., Leasure, J. L., Tillerson, J. L., & Bland, S. T. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00005-8 · Cited by 1,354
Self-citationNeuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Research works printed but not linked: 4
- Tanner, 1990, Neurology, 40, 17
- Parsons, 1994, Crit. Rev. Neurobiol., 8, 189
- Walsh, 1992, J. Pharmacol. Exp. Ther., 263, 617
- Schallert, 1988, Vol. 515, 108
Cited by
Items 501–600 of 913
Jiao, F., Meng, L., Du, K., & Li, X. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01195 · Cited by 33
“In the striatum of parkin knockdown mice, parkin deletion resulted in reduced synaptic excitability, increased dopamine concentration in the extracellular space, and nigrostriatal deficits, yet the number of dopaminergic neurons in the substantia nigra was normal (Goldberg et al., 2003).”
BackgroundOrdóñez-Librado, J. L., Gutiérrez-Valdez, A. L., Colín-Barenque, L., Anaya-Martínez, V., Díaz-Bech, P., & Ávila-Costa, M. R. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.05.012 · Cited by 32
Genetics of neurological disorders
Faghihi, M. A., Mottagui‐Tabar, S., & Wahlestedt, C. (2004) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.4.3.317 · Cited by 26
Wang, Z., Chan, S.-W., Zhao, H., Miu, K.-K., & Chan, W. (2023) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2022.406 · Cited by 33
Can overexpression of parkin provide a novel strategy for neuroprotection in Parkinson's disease?
Ulusoy, A., & Kirik, D. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.04.026 · Cited by 27
“Nevertheless, several parkin deficient mouse lines have been developed by exon deletions (Goldberg et al., 2003; Von Coelln et al., 2004; Zhu et al., 2007).”
BackgroundLoss of Non-Apoptotic Role of Caspase-3 in the PINK1 Mouse Model of Parkinson’s Disease
Imbriani, P., Tassone, A., Meringolo, M., Ponterio, G., Madeo, G., Pisani, A., Bonsi, P., & Martella, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143407 · Cited by 32
Macroautophagy and Mitophagy in Neurodegenerative Disorders: Focus on Therapeutic Interventions
Magalhães, J. D., Fão, L., Vilaça, R., Cardoso, S. M., & Rego, A. C. (2021) · Biomedicines · doi:10.3390/biomedicines9111625 · Cited by 30
“Such ablation is able to produce mild nigrostriatal defects [229], associated with altered mitochondrial morphology [230].”
BackgroundMitophagy and Neuroinflammation: A Compelling Interplay
Charmpilas, N., Fang, E. F., & Palikaras, K. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220628153632 · Cited by 30
“The link between mitophagy and neuroinflammation remained largely ambiguous since several studies using mouse models deficient for either PINK1 or Parkin failed to recapitulate phenotypes reminiscent of PD pathology [28-31].”
Safadi, S. S., Barber, K. R., & Shaw, G. S. (2011) · Biochemistry · doi:10.1021/bi200065g · Cited by 27
Parkin interacts with Klokin1 for mitochondrial import and maintenance of membrane potential
Kuroda, Y., Sako, W., Goto, S., Sawada, T., Uchida, D., Izumi, Y., Takahashi, T., Kagawa, N., Matsumoto, M., Matsumoto, M., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr530 · Cited by 29
Behavioral analysis of motor and non-motor impairment in rodent models of Parkinson's disease
Sheta, R., Bérard, M., Musiol, D., Martínez-Drudis, L., & Oueslati, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1464706 · Cited by 35
Mitochondrial Acetylation and Genetic Models of Parkinson's Disease
Auburger, G. W. J., Gispert, S., & Jendrach, M. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-394625-6.00006-4 · Cited by 30
PICK1 inhibits the E3 ubiquitin ligase activity of Parkin and reduces its neuronal protective effect
He, J., Xia, M., Yeung, P. K. K., Li, J., Li, Z., Chung, K. K. K., Chung, S. K., & Xia, J. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716506115 · Cited by 27
“However, Parkin (1-463) lacking the PDZ-binding motif retained the ability to bind to PICK1 (Fig.”
BackgroundA Healthy Heart and a Healthy Brain: Looking at Mitophagy
Luo, H., Zhang, R., Krigman, J., McAdams, A., Ozgen, S., & Sun, N. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00294 · Cited by 25
Kohta, R., Kotake, Y., Hosoya, T., Hiramatsu, T., Otsubo, Y., Koyama, H., Hirokane, Y., Yokoyama, Y., Ikeshoji, H., Oofusa, K., et al. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06576.x · Cited by 26
Animal models of Parkinson's disease: Similarities and differences between the disease and models
Hattori, N., & Sato, S. (2007) · Neuropathology · doi:10.1111/j.1440-1789.2007.00842.x · Cited by 27
“Until now several lines of parkin-null mice has been generated; however, the mechanisms underling the cause of AR-JP are less well defined, because most (if not all) substrates for parkin reported so far remain unchanged irrespective of parkindeficiency.(16,18) In addition, most parkin-null mice revealed no phenotypes…”
BackgroundMao, L., Zabel, C., Herrmann, M., Nolden, T., Mertes, F., Magnol, L., Chabert, C., Hartl, D., Hérault, Y., Delabar, J. M., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001218 · Cited by 30
“For example, in protein patterns obtained by two-dimensional gel electrophoresis (2-DE) of brain proteins from a mouse model for Parkinson’s disease deficient of the parkin protein [1] and from a transgenic mouse model for Huntington’s disease [2], we detected 15 and 40 variant proteins, respectively [3,4].”
Bjerre, D., Madsen, L. B., Bendixen, C., & Larsen, K. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.167 · Cited by 26
Ubiquitin Ligase RBX2/SAG Regulates Mitochondrial Ubiquitination and Mitophagy
Wang, W., Li, E., Zou, J., Qu, C., Ayala, J. D., Wen, Y., Islam, M. S., Weintraub, N. L., Fulton, D. J., Liang, Q., et al. (2024) · Circulation Research · doi:10.1161/circresaha.124.324285 · Cited by 29
Loss of Parkin Results in Altered Muscle Stem Cell Differentiation during Regeneration
Esteca, M. V., Severino, M. B., Silvestre, J. G., dos Santos, G. P., Tamborlin, L., Luchessi, A. D., Moriscot, A. S., Gustafsson, Å. B., & Baptista, I. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218007 · Cited by 31
“The Parkintm1Shn (Parkin−/−) mice were generated by [36], provided by the Multidisciplinary Center for Biological Research (CEMIB) and transported to the School of Applied Sciences of the University of Campinas in Limeira (São Paulo, Brazil).”
MethodDisrupted myelination network in the cingulate cortex of Parkinson's disease
Xie, S., Yang, J., Huang, S., Fan, Y., Xu, T., He, J., Guo, J., Ji, X., Wang, Z., Li, P., et al. (2022) · IET Systems Biology · doi:10.1049/syb2.12043 · Cited by 27
Fleming, S. M. (2009) · International review of neurobiology · doi:10.1016/s0074-7742(09)89003-x · Cited by 25
Self-citationRNA metabolism in the pathogenesis of Parkinson׳s disease
Lu, B., Gehrke, S., & Wu, Z. (2014) · Brain Research · doi:10.1016/j.brainres.2014.03.003 · Cited by 28
“Analyses of parkin KO mice have emphasized the importance of Parkin in regulating evoked dopamine release and striatal synaptic plasticity in the nigrostriatal pathway (Goldberg et al., 2003).”
Mouse models of Parkinson's disease associated with mitochondrial dysfunction
Pickrell, A. M., Pinto, M., & Moraes, C. T. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.08.002 · Cited by 28
“It exhibited only mild phenotypes on beam traverse or sticker removal examinations monitoring fine motor skills, and slight DA abnormalities or loss; it did not show any neurodegeneration and only its medium spiny neurons seemed to be affected, being less sensitive to evoked action potentials (Goldberg et al., 2003).”
BackgroundKhan, N., Pelletier, D., McAlear, T. S., Croteau, N., Veyron, S., Bayne, A. N., Black, C., Ichikawa, M., Khalifa, A. A. Z., Chaaban, S., et al. (2021) · Structure · doi:10.1016/j.str.2021.01.001 · Cited by 24
Shires, S. E., Quiles, J. M., Najor, R. H., Leon, L. J., Cortez, M. Q., Lampert, M. A., Mark, A., & Gustafsson, Å. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-65438-7 · Cited by 26
Autophagy deficiency abolishes liver mitochondrial DNA segregation
Tostes, K., dos Santos, A. C., Alves, L. D. O., Bechara, L. R. G., Marascalchi, R., Macabelli, C. H., Grejo, M. P., Festuccia, W. T., Gottlieb, R. A., Ferreira, J. C. B., et al. (2022) · Autophagy · doi:10.1080/15548627.2022.2038501 · Cited by 28
“mtDNA segregation, we assessed NZB levels in heteroplasmic prkn-null mice [49] (hereafter termed prkn).”
BackgroundNeurodegeneration models in Parkinson’s disease: cellular and molecular paths to neuron death
Álvarez‐Luquín, D. D., González-Fernández, R. R., Torres-Velasco, M. E., Ichikawa-Escamilla, E., Arce-Sillas, A., Martínez‐Martínez, E., Miranda-Narváez, C. L., Rodríguez-Ramírez, J. F., & Adalid-Peralta, L. V. (2025) · Behavioral and Brain Functions · doi:10.1186/s12993-025-00279-w · Cited by 31
“Rodents lacking Parkin function do not show signs of dopaminergic neurodegeneration and have mild features of PD [187].”
Parkin negatively regulates the antiviral signaling pathway by targeting TRAF3 for degradation
Xin, D., Gu, H., Liu, E., & Sun, Q. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001201 · Cited by 26
“5day embryos of Parkin / and Parkin / mice (41) (The Jackson Laboratory).”
BackgroundContrast-enhanced ultrasound of transplant organs — liver and kidney — in children
Franke, D., Daugherty, R. J., Ključevšek, D., Ntoulia, A., Rafailidis, V. D., Takahashi, M. S., Torres, A., Viteri, B., & Volberg, F. M. (2021) · Pediatric Radiology · doi:10.1007/s00247-020-04867-y · Cited by 23
Aguiar, A. S., Tristão, F. S. M., Amar, M., Chevarin, C., Lanfumey, L., Mongeau, R., Corti, O., Prediger, R. D., & Raisman‐Vozari, R. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9389-0 · Cited by 25
“Parkin exon 3 mice show increased levels of extracellular DA (Goldberg et al. 2003; Itier et al. 2003) and reduced striatal Fig.”
InfluentialKinase signaling pathways as potential targets in the treatment of Parkinson’s disease
Greggio, E., & Singleton, A. (2007) · Expert Review of Proteomics · doi:10.1586/14789450.4.6.783 · Cited by 24
Nomura, J., Hosoi, T., Kaneko, M., Ozawa, K., Nishi, A., & Nomura, Y. (2016) · Medical Sciences · doi:10.3390/medsci4030014 · Cited by 25
The Ubiquitin–Proteasome Pathway is Necessary for Maintenance of the Postmitotic Status of Neurons
Staropoli, J. F., & Abeliovich, A. (2005) · Journal of Molecular Neuroscience · doi:10.1385/jmn:27:2:175 · Cited by 23
“This might partly explain the subtle phenotype of parkin-deficient mice (Goldberg et al., 2003, Itier et al., 2003; Von Coelln et al., 2004).”
BackgroundMohamed, N., Larroquette, F., Beitel, L. K., Fon, E. A., & Durcan, T. M. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-181515 · Cited by 26
Mitophagy in the aging nervous system
Rappe, A., & McWilliams, T. G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.978142 · Cited by 23
“This is not surprising because animal models and patients lacking PINK1 or Parkin do not manifest overt mitochondrial phenotypes, or a build-up of damaged mitochondria within tissues (Goldberg et al., 2003; Perez and Palmiter 2005; Yang et al., 2019;Wrighton et al., 2021).”
Common Fragile Site Tumor Suppressor Genes and Corresponding MouseModels of Cancer
Drusco, A., Pekarsky, Y., Costinean, S., Antenucci, A., Conti, L., Volinia, S., Aqeilan, R. I., Huebner, K., & Zanesi, N. (2010) · BioMed Research International · doi:10.1155/2011/984505 · Cited by 24
Parkin Modulates Gene Expression in Control and Ceramide-Treated PC12 Cells
Unschuld, P. G., Dächsel, J. C., Darios, F. D., Kohlmann, A., Casademunt, E., Lehmann‐Horn, K., Dichgans, M., Ruberg, M., Brice, A., Gasser, T., et al. (2006) · Molecular Biology Reports · doi:10.1007/s11033-005-3961-5 · Cited by 28
Animal Models of Parkinson’s Disease
Blesa, J., Trigo‐Damas, I., Quiroga‐Varela, A., & del Rey, N. L. (2016) · InTech eBooks · doi:10.5772/63328 · Cited by 31
Altered Hippocampal Synaptic Physiology in Aged Parkin-Deficient Mice
Hanson, J. E., Orr, A., & Madison, D. V. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-010-8113-y · Cited by 23
Role of Mitochondrial Dysfunction in Parkinson???s Disease: Implications for Treatment
Ramsey, C. P., & Giasson, B. I. (2007) · Drugs & Aging · doi:10.2165/00002512-200724020-00002 · Cited by 27
RIPOR2-mediated autophagy dysfunction is critical for aminoglycoside-induced hearing loss
Li, J., Liu, C., Müller, U., & Zhao, B. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.08.011 · Cited by 23
Transgenic Mouse Models for the Study of Neurodegenerative Diseases
Marín‐Moreno, A., Canoyra, S., Fernández‐Borges, N., Espinosa, J. C., & Torres, J. M. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2801021 · Cited by 22
“Models just showed partial and mild signs of PD like deficits in the dopamine system and motor symptoms, but none or only moderate loss of dopaminergic neurons was detected [47–50 , 58”
BackgroundMitophagy and long-term neuronal homeostasis
Markaki, M., Tsagkari, D., & Tavernarakis, N. (2023) · Journal of Cell Science · doi:10.1242/jcs.260638 · Cited by 23
Protein quality control in the endoplasmic reticulum
Koenig, P.-A., & Ploegh, H. L. (2014) · F1000Prime Reports · doi:10.12703/p6-49 · Cited by 24
“Parkin: viable and fertile but with motor and cognitive defects [92-98]”
BackgroundSahún, I., Maréchal, D., Pereira, P. L., Nalesso, V., Gruart, A., García, J. M. D., Antonarakis, S. E., Dierssen, M., & Hérault, Y. (2014) · Genetics · doi:10.1534/genetics.114.165241 · Cited by 25
“We detected also variations of Park2 , a regulator of dopamine production in the striatum, whose loss decreases synaptic excitability (Goldberg et al. 2003).”
BackgroundMitochondrial defects and neurodegeneration in mice overexpressing wild-type or G399S mutant HtrA2.
Casadei, N., Sood, P., Ulrich, T., Fallier-Becker, P., Kieper, N., Helling, S., May, C., Glaab, E., Chen, J., Nuber, S., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv485 · Cited by 15
“Motor coordination and fine movement alterations were tested in challenging beam walk during dark phase as described previously (33).”
MethodUbiquitin-protein ligase parkin and its role in the development of Parkinson’s disease
Бунеева, О. А., & Medvedev, A. E. (2006) · Biochemistry (Moscow) · doi:10.1134/s0006297906080050 · Cited by 22
Hennis, M. R., Seamans, K. W., Marvin, M. A., Casey, B. H., & Goldberg, M. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084894 · Cited by 26
“Previous reports have indicated normal locomotor activity in Parkin-/- and DJ-1-/- mice [19,33,78].”
BackgroundMethodResultSelf-citationErb, M. L., Sipple, K., Levine, N. D., Chen, X., & Moore, D. J. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00748-5 · Cited by 22
“A similar phenomenon is observed in parkin KO mice, where the Cre-mediated, adult-onset KO of parkin is sufficient to induce progressive neurodegeneration whereas germline KO mice consistently fail to do so with advanced age 32-34 .”
BackgroundScott, L., Karuppagounder, S. S., Neifert, S., Kang, B. G., Wang, H., Dawson, V. L., & Dawson, T. M. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.0545-22.2022 · Cited by 20
Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2
Tong, Y., & Shen, J. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120112 · Cited by 24
Self-citationPsychotropic and Neurotropic Activity
Vogel, H. G. (2007) · Springer eBooks · doi:10.1007/978-3-540-70995-4_6 · Cited by 24
Huang, G., Bloodgood, D. W., Kang, J., Shahapal, A., Chen, P., Kaganovsky, K., Kim, J., Ding, J., & Shen, J. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.0140-22.2022 · Cited by 22
“The procedures of the rotarod have been described previously (Goldberg et al., 2003).”
InfluentialSelf-citationStudies of Depression-Related States in Animal Models of Parkinsonism
Schintu, N., Zhang, X., & Svenningsson, P. (2012) · Journal of Parkinson s Disease · doi:10.3233/jpd-2012-12076 · Cited by 24
“Several genetic lines carrying a deletion of different exons in the parkin gene have also been generated [59–62], but none of them showed a consistent phenotype, probably due to differ-”
BackgroundProteomic studies associated with Parkinson’s disease
Kasap, M., Akpınar, G., & Kanlı, A. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1291344 · Cited by 24
“Several groups have generated a Parkin knockout mouse model to facilitate the investigation of the functional consequences of gene inactivation [114,115,188].”
BackgroundCharacterization of Dopaminergic System in the Striatum of Young Adult Park2−/− Knockout Rats
Gemechu, J. M., SHARMA, A. K., Yu, D., Xie, Y., Merkel, O. M., & Moszczyńska, A. (2018) · Scientific Reports · doi:10.1038/s41598-017-18526-0 · Cited by 17
Yokota, M., Kakuta, S., Shiga, T., Ishikawa, K., Okano, H., Hattori, N., Akamatsu, W., & Koike, M. (2021) · Molecular Brain · doi:10.1186/s13041-021-00771-0 · Cited by 26
Midbrain neuronal cultures from parkin mutant mice are resistant to nitric oxide-induced toxicity
Solano, R. M., Menéndez, J., Casarejos, M. J., Rodríguez‐Navarro, J. A., de Yébenes, J. G., & Mena, M. A. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.03.027 · Cited by 28
Stable Isotope Labeling and Label-Free Proteomics of Drosophila parkin Null Mutants
Xun, Z., Kaufman, T. C., & Clemmer, D. E. (2009) · Journal of Proteome Research · doi:10.1021/pr9006238 · Cited by 21
Literature-Related Discovery (LRD)
Kostoff, R. N., Block, J. A., Solka, J. L., Briggs, M. B., Rushenberg, R. L., Stump, J. A., Johnson, D., Lyons, T. J., & Wyatt, J. R. (2007) · Defense Technical Information Center (DTIC) · doi:10.21236/ada473438 · Cited by 19
Prkn knockout mice show autistic-like behaviors and aberrant synapse formation
Huo, Y., Lü, W., Tian, Y., Hou, Q., & Man, H. (2022) · iScience · doi:10.1016/j.isci.2022.104573 · Cited by 21
“14 iScience 25, 104573, July 15, 2022 the substantia nigra in mice of 6–18 months or 18–22 months old (Goldberg et al., 2003; Perez and Palmiter, 2005), suggesting that the Prkn KO mouse may have features of other neurological disorders.”
BackgroundResultParkinson's disease: animal models
Betarbet, R. S., & Greenamyre, J. T. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83011-9 · Cited by 20
Mitochondrial disfunction in Parkinson's disease
Бунеева, О. А., & Medvedev, A. E. (2011) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20115703246 · Cited by 18
Parkinson’s disease research: adopting a more human perspective to accelerate advances
Marshall, L. J., & Willett, C. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.010 · Cited by 19
Kim, K., & Sack, M. N. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dc5d · Cited by 24
Parkin promotes proteasomal degradation of synaptotagmin IV by accelerating polyubiquitination
Kabayama, H., Tokushige, N., Takeuchi, M., Kabayama, M., Fukuda, M., & Mikoshiba, K. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.02.006 · Cited by 16
“Notably, the parkin, PINK1, and DJ-1 mutations in knockout (KO) mice (even triple-KO mice) do not cause specific degeneration of nigral dopamine neurons, in contrast to human patients bearing loss-of-function mutations (Goldberg et al., 2003; Goldberg et al., 2005; Kitada et al., 2007; Kitada et al., 2009a).”
BackgroundMacCormac, L. P., Muqit, M. M. K., Faulkes, D. J., Wood, N. W., & Latchman, D. S. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03659.x · Cited by 23
“knockout mice do not exhibit nigro-striatal cell loss, although recent studies have revealed mitochondrial deficits and increased oxidative damage (Goldberg et al., 2003; Itier et al., 2003; Palacino et al., 2004).”
BackgroundObara, Y., & Ishii, K. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00663 · Cited by 17
Deletion of the Creatine Transporter (Slc6a8) in Dopaminergic Neurons Leads to Hyperactivity in Mice
Abdulla, Z. I., Pahlevani, B., Lundgren, K. H., Pennington, J. L., Udobi, K. C., Seroogy, K. B., & Skelton, M. R. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-01405-w · Cited by 18
PARKIN is not required to sustain OXPHOS function in adult mammalian tissues
Filograna, R., Gerlach, J., Choi, H.-N., Rigoni, G., Barbaro, M., Oscarson, M., Lee, S., Tiklová, K., Ringnér, M., Koolmeister, C., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00707-0 · Cited by 19
Parkin modulates the hepatocellular carcinoma microenvironment by regulating PD-1/PD-L1 signalling
Ye, G., Sun, X., Li, J., Pu, M., & Zhang, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.045 · Cited by 21
“First, we verified the genotype of mice through PCR analysis [31], and the resulting 250 bp and 500 bp PCR products corresponded to Park2 +/+ mice and Park2 -/- mice, respectively (Fig.”
Costa, D. K., Huckestein, B. R., Edmunds, L. R., Petersen, M. C., Nasiri, A. R., Butrico, G. M., Abulizi, A., Harmon, D. B., Lu, C., Mantell, B. S., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00042.2016 · Cited by 19
Managing risky assets – mitophagy in vivo
Narendra, D. P. (2021) · Journal of Cell Science · doi:10.1242/jcs.240465 · Cited by 18
The Ubiquitin Proteasome System as a Therapeutic Area in Parkinson’s Disease
Kumar, S., Mattern, M. R., Goldberg, M. S., & Butt, T. R. (2023) · NeuroMolecular Medicine · doi:10.1007/s12017-023-08738-1 · Cited by 16
“For example, the loss of PINK1 or Parkin in mice results in no overt PD phenotype, which may reflect compensatory mechanisms in the organism (Goldberg et al., 2003; Perez & Palmiter, 2005).”
Self-citationThe Genetics of Alzheimer’s Disease and Parkinson’s Disease
Bekris, L. M., Yu, C., Bird, T. D., & Tsuang, D. W. (2010) · Advances in neurobiology · doi:10.1007/978-1-4419-7104-3_21 · Cited by 19
“and glutaminergic transmission alterations and do not suffer nigral neuronal degeneration or clinical manifestations of Parkinsonism (Goldberg et al., 2003; Itier et al., 2003) and reduced numbers of noradrenergic neurons in the locus ceruleus were reported in one strain (Von Coelln et al.”
BackgroundAberrant striatal synaptic plasticity in monogenic parkinsonisms
Madeo, G., Martella, G., Schirinzi, T., Ponterio, G., Shen, J., Bonsi, P., & Pisani, A. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.07.065 · Cited by 21
Self-citationRoux, P., Boitard, S., Blum, Y., Parks, B. W., Montagner, A., Mouisel, É., Djari, A., Esquerré, D., Désert, C., Boutin, M., et al. (2015) · G3 Genes Genomes Genetics · doi:10.1534/g3.115.016865 · Cited by 21
Parkin and 𝛂-Synuclein: Opponent Actions in The Pathogenesis of Parkinson’S Disease
Baptista, M. J., Cookson, M., & Miller, D. W. (2004) · The Neuroscientist · doi:10.1177/1073858403260392 · Cited by 22
Diaminodiphenyl sulfone–induced parkin ameliorates age-dependent dopaminergic neuronal loss
Lee, Y.-I., Kang, H., Ha, Y. W., Chang, K.-Y., Cho, S.-C., Song, S. O., Kim, H., Jo, A., Khang, R., Choi, J.-Y., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.11.008 · Cited by 16
The compartmentalised nature of neuronal mitophagy: molecular insights and implications
Borbolis, F., & Palikaras, K. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.31 · Cited by 18
“…in PINK1 and Parkin Drosophila mutants, that are not observed in the corresponding murine models, as it is possible that mice deploy additional quality control mechanisms to sustain mitochondrial quality during ageing, which are not activated or even present in flies (Refs 50, 51, 131 – 133 ).”
Mohammed, O. A., Elballal, M. S., El-Husseiny, A. A., Khidr, E. G., Tabaa, M. M. E., Elazazy, O. E., Abd‐Elmawla, M. A., Elesawy, A. E., Ibrahim, H. M., Abulsoud, A. I., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.155023 · Cited by 19
Narwal, S., Singh, A., & Tare, M. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1295805 · Cited by 18
Ziegler, C. G. K., Peng, M., Falk, M. J., Polyák, E., Tsika, E., Ischiropoulos, H., Bakalar, D., Blendy, J. A., & Gasser, D. L. (2011) · Mitochondrion · doi:10.1016/j.mito.2011.09.011 · Cited by 16
“…that either involve mutations at candidate gene loci or injection of neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6- hydroxydopamine (6-OHDA), or rotenone (Abeliovich et al., 2000; Betarbet et al., 2000; Bloem et al., 1990; Goldberg et al., 2003; Sauer and Oertel, 1994).”
BackgroundCharacterization of Motor and Non-Motor Behavioral Alterations in the Dj-1 (PARK7) Knockout Rat
Kyser, T. L., Dourson, A. J., McGuire, J. L., Hemmerle, A. M., Williams, M. T., & Seroogy, K. B. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-01358-0 · Cited by 17
Dopamine receptor pharmacology
Mailman, R. B., & Huang, X. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83004-1 · Cited by 19
USP14 inhibition enhances Parkin-independent mitophagy in iNeurons
Bernardo, G., Prado, M. A., Dashtmian, A. R., Favaro, M., Mauri, S., Borsetto, A., Marchesan, E., Paulo, J. A., Gygi, S. P., Finley, D. J., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107484 · Cited by 20
Mechanisms for sperm mitochondrial removal in embryos
de Melo, K. P., & Camargo, M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118916 · Cited by 19
Kostrzewa, R. M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02479-4 · Cited by 17
“With mutations in PRKN there is little motor deficit accompanied by an undiscernible dopaminergic degeneration (Goldberg et al. 2003; Perez and Palmiter 2005).”
BackgroundKim, J. J., Daadi, E. W., Oh, T. T., Daadi, E. S., & Daadi, M. M. (2022) · Genes · doi:10.3390/genes13111937 · Cited by 14
Trabjerg, M. S., Andersen, D. C., Huntjens, P., Mørk, K., Warming, N., Kullab, U. B., Skjønnemand, M.-L. N., Oklinski, M. K., Oklinski, K. E., Bolther, L., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00450-y · Cited by 16
Parkin coregulates glutathione metabolism in adult mammalian brain
Kodsi, D. N. E., Tokarew, J. M., Sengupta, R., Lengacher, N. A., Chatterji, A., Nguyen, A., Boston, H., Jiang, Q., Palmberg, C., Pileggi, C. A., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01488-4 · Cited by 15
“nigra of genomically prkn-deficient mice [15, 19, 37, 38, 47, 57].”
Pang, M., Song, X., Miao, Y., Wang, Y., Zhou, C., Geng, Z., Du, J., Moussian, B., Su, Y., Liu, X., et al. (2023) · BMEMat · doi:10.1002/bmm2.12019 · Cited by 15
Mitochondrial Regulation by PINK1-Parkin Signaling
Imai, Y. (2012) · ISRN Cell Biology · doi:10.5402/2012/926160 · Cited by 17
Rethinking energy in parkinsonian motor symptoms: a potential role for neural metabolic deficits
Amano, J., Kegelmeyer, D. A., & Hong, S. L. (2015) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00242 · Cited by 18
“129S4-PARK2tm1SHN /J) results in mitochondrial dysfunction and behavioral impairments in the absence of nigral degeneration (Goldberg et al., 2003).”
BackgroundBézard, E. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00003 · Cited by 17
“The same remark applies to the more recently developed parkin-knockout mice (e.g. see Goldberg et al., 2003; Perez and Palmiter, 2005) and DJ-1 knockout mice (e.g. see Goldberg et al., 2005; Kim et al., 2005), which also showed no dopaminergic neuronal death.”
BackgroundParkin‐mediated ubiquitination regulates phospholipase C‐γ1
Dehvari, N., Matton, A., Flores‐Morales, A., Mateos, L., Chuan, Y.-C., Goldberg, M. S., Cookson, M., Cowburn, R. F., & Cedazo-Mínguez, Á. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00443.x · Cited by 17
“Whole brains from four parkin knockout mice [23] and four wild-type littermates were also used.”
MethodSelf-citationHow proteomics reveals potential biomarkers in brain diseases
Schmidt, O., Schulenborg, T., Meyer, H. E., Marcus, K., & Hamacher, M. (2005) · Expert Review of Proteomics · doi:10.1586/14789450.2.6.901 · Cited by 19
Mitochondria‐derived vesicles: A promising and potential target for tumour therapy
Peng, X. Y., Gao, Y., Liu, J., Shi, X., Li, W., Ma, Y., Li, X., & Li, H. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70320 · Cited by 18
“103, 104 MDVs are released within a short frame of 2–6 h after exposure to mild stress, such as treatment with antimycin A, whereas mitophagy typically occurs between 12 and 24 h after the stress onset.”
Bury, A. G., & Pienaar, I. S. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.03.007 · Cited by 14
Metadata
- Authors
- Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., Gajendiran, M., Roth, B. L., Chesselet, M.-F., Maidment, N. T., Levine, M. S., & Shen, J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California, Los Angeles (US)
- Case Western Reserve University (US)
- Corresponding author
- Shen, Jie
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 278
- Issue
- 44
- Pages
- 43628-43635
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2088962120
- Cited by
- 913
- References
- 72
- Citations by year
- 2026: 8 · 2025: 25 · 2024: 35 · 2023: 27 · 2022: 45 · 2021: 39 · 2020: 39 · 2019: 25 · 2018: 39 · 2017: 40 · 2016: 29 · 2015: 34 · 2014: 41 · 2013: 43 · 2012: 36
- FWCI
- 33.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6206 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkin, Parkinson's disease, nigrostriatal pathway, dopaminergic neurons, substantia nigra, striatum, dopaminergic modulation, synaptic excitability, spiny neurons, E3 ubiquitin ligase, alpha-synuclein, synphilin-1, neuronal survival
- MeSH terms
- Alleles, Animals, Behavior, Animal, Brain, Chromatography, High Pressure Liquid, Disease Models, Animal, Dopamine, Electrophysiology, Mice, Transgenic, Models, Genetic, Neurons, Parkinson Disease, Receptors, Dopamine, Substantia Nigra, Time Factors, Blotting, Western, Germ-Line Mutation, Ubiquitin-Protein Ligases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.